Claims
- 1. An N-substituted 3-azabicyclo[3.2.0]heptane compound of formula I in whichR1 is chlorine, R2 is C1-C3-alkyl or cyclopropyl, and R3 is hydrogen, or a salt thereof with a physiologically tolerated acid.
- 2. The compound of formula I defined in claim 1, wherein R1 is bonded in para position of the phenyl ring.
- 3. The compound of formula I defined in claim 1, wherein R2 is methyl or ethyl, or the salt thereof with the pysiologically tolerated acid.
- 4. The compound of formula I defined in claim 1, which is selected from the group consisting of(+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo[3.2.0]-heptan-3-yl]ethyl]-3-methyl-2H-1,3-dihydrobenzimidazol-2-one, and (+)-(1S,5R,6S-)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo[3.2.0]-heptan-3-yl]ethyl]-3-ethyl-2H-1,3-dihydrobenzimidazol-2-one.
- 5. The salt of the compound of formula I defined in claim 1, which is selected from the group consisting of(+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-methyl-2H-1,3-dihydrobenzimidazol-2-one tartrate×2H2O, (+)-(1S,5R,6S)-exo-1-[2-[6-(4chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-ethyl-2H-1,3-dihydrobenzimidazol-2-one×HCl, (+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-n-propyl-2H-1,3-dihydrobenzimidazol-2-one×HCl, (+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-methyl-5-chloro-2H-1,3-dihydrobenzimidazol-2-one×HCl, (+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-methyl-6-chloro-2H-1,3-dihydrobenzimidazol-2-one×HCl, and (+)-(1S,5R,6S)-exo-1-[2-[6-(4-chlorophenyl)-3-azabicyclo-[3.2.0]heptan-3-yl]ethyl]-3-cyclopropyl-2H-1,3-dihydrobenzimidazol-2-one×HCl.
- 6. A pharmaceutical composition comprising an effective amount of the compound of formula I defined in claim 1 and at least one conventional carrier or diluent.
- 7. A method of treating a patient in need of such treatment with a neuroleptic, antidepressant, sedative, hypnotic, CNS protective agent or an agent for the treatment of cocaine dependency, which comprises administering to said patient an effective amount of the compound of formula I defined in claim 1.
- 8. The method of claim 7, wherein the compound of formula I is used as a neuroleptic.
- 9. The method of claim 7, wherein the compound of formula I is administered to the patient orally in a daily dose of from 1 to 100 mg per kg body weight of the patient.
- 10. The method of claim 7, wherein the compound of formula I is administered to the patient parenterally in a daily dose of from 0.1 to 10 mg per kg body weight of the patient.
Priority Claims (2)
Number |
Date |
Country |
Kind |
198 36 404 |
Aug 1998 |
DE |
|
100 05 942 |
Feb 2000 |
DE |
|
Parent Case Info
This application is a 371 of PCT/EP99/05166 filed Jul. 20, 1999.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4254127 |
Vandenbeck et al. |
Mar 1981 |
A |
5475105 |
Steiner et al. |
Dec 1995 |
A |
6028073 |
Steiner et al. |
Feb 2000 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
WO 9400431 |
Jan 1994 |
WO |
WO 9400458 |
Jan 1994 |
WO |
WO 9515312 |
Jun 1995 |
WO |
WO 9604245 |
Feb 1996 |
WO |
WO 9604272 |
Feb 1996 |
WO |
Non-Patent Literature Citations (3)
Entry |
Vernin et al. “Synthesis of 1-Alkyl and 1,3-Dialkyl-2-Benzimidazalones from 1-Alkenyl-2_Benzimidazolones using Phase-Transfer Catalysts Technique” J. Heterocyclic Chem. vol. 18 (1985) pp. 85-89. |
Steiner et al. “Diastereoselective Synthesis of Exo-6-Aryl-3-Aza-Bicyclo [3,2,0]Heptane Derivatives by Intramolecular [2+2] Photocycloadditions of Diallyic Amines” Heterocycles vol. 40, (1995) pp. 319-350. |
H.Sucker et al. “Hilfsstoffe für Arzneiformen” Pharm. Technologies (1978) pp. 280-360. |